Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE
NCT06863480Phase 1Recruiting
- Sponsor
- University of Florida
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bat1806 in aneurysmal subarachnoid hemorrhage (SAH) and delayed cerebral ischemia (DCI), sponsored by University of Florida. Primary endpoints: Number of participants with elevation of liver transaminases up to 21 days, Number of participants with neutropenia up to 21 days and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
bat1806
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)delayed cerebral ischemia (DCI)
Beyond the preview
Go deeper on NCT06863480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863480.